Jacob Levi

Can the UNAIDS 90-90-90 target be achieved? A systematic analysis of national HIV treatment cascades

Jacob Levi, Alice Raymond, Anton Pozniak et al. · BMJ Global Health · 2016 · 342 citations · Full text

Public Health, Health Policy, Infectious Disease Control +17

The Joint United Nations Programme on HIV/AIDS 95–95–95 targets: worldwide clinical and cost benefits of generic manufacture

Katherine Heath, Jacob Levi, Andrew Hill · AIDS · 2021 · 145 citations · Full text

Public Health, Health Policy, Pharmacoeconomics +17

Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial

Anahita Sadeghı, Ali Asgari, Alireza Norouzi et al. · Journal of Antimicrobial Chemotherapy · 2020 · 132 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +12

Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial

Hamideh Abbaspour Kasgari, Siavash Moradi, Amir Mohammad Shabani et al. · Journal of Antimicrobial Chemotherapy · 2020 · 96 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

The Joint United Nations Programme on HIV/AIDS 95-95-95 targets: worldwide clinical and cost benefits of generic manufacture.

Katherine Heath, Jacob Levi, Andrew Hill · PubMed · 2021 · 80 citations

Public Health, Pharmaceutical Policy, Pharmacoeconomics +17